YS Biopharma Announces Name Change to LakeShore Biopharma
YS Biopharma Announces Name Change to LakeShore Biopharma
GAITHERSBURG, Md., May 24, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced it is changing its legal name from "YS Biopharma Co., Ltd." to "LakeShore Biopharma Co., Ltd".
馬里蘭州蓋瑟斯堡，2024 年 5 月 24 日 /PRNewswire/ — 致力於發現、開發、製造和交付用於傳染病和癌症的新一代疫苗和治療性生物製劑的全球生物製藥公司YS Biopharma有限公司（Nasdaq: YS）（“YS Biopharma” 或 “公司”）今天宣佈其法定名稱從 “YS Biopharma Co..，有限公司” 改爲 “湖岸生物製藥有限公司”。
Dr. David Shao, Director, President, Co-Chief Executive Officer, and Chief Business Officer of the Company, commented, "We have decided to change our company name to LakeShore Biopharma to align with our global market positioning and international brand image. This change marks one of the first steps for us to expand our market reach, and we are eager to move forward and drive success under our new company name."
公司董事、總裁、聯席首席執行官兼首席商務官邵大衛博士評論說：“我們決定將公司名稱改爲LakeShore Biopharma，以符合我們的全球市場定位和國際品牌形象。這一變化標誌着我們擴大市場覆蓋範圍的第一步，我們渴望以新的公司名稱向前邁進並推動成功。”
The name change and trading symbol change will not affect any rights of shareholders or the Company's operations and financial position. The Company's ordinary shares and warrants will continue to be listed on the Nasdaq. Effective with the opening of the trading day on May 28, 2024, the ticker symbol of the Company's ordinary shares and warrants will change from "YS" to "LSB" and from "YSBPW" to "LSBPW", respectively. There is no action required by the Company's current shareholders with respect to the company name or ticker symbol changes. The Company's CUSIP will not change in connection with the name change.
名稱變更和交易代碼變更不會影響股東的任何權利或公司的運營和財務狀況。該公司的普通股和認股權證將繼續在納斯達克上市。自2024年5月28日交易日開盤起，公司普通股和認股權證的股票代碼將分別從 “YS” 變爲 “LSB”，從 “YSBPW” 更改爲 “LSBPW”。公司現任股東無需就公司名稱或股票代碼的變更採取任何行動。公司的CUSIP不會因名稱變更而發生變化。
About LakeShore Biopharma (formerly known as YS Biopharma)
關於 LakeShore Biopharma（前身爲 YS Biopharma）
LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The Company operates in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit investor.ysbiopharma.com.
LakeShore Biopharma，前身爲YS Biopharma，是一家全球生物製藥公司，致力於發現、開發、製造和交付用於傳染病和癌症的新一代疫苗和治療性生物製劑。它開發了專有的PIKA免疫調節技術平台和針對狂犬病、冠狀病毒、乙型肝炎、流感、帶狀皰疹和其他病毒感染的新一代預防和治療生物製劑。該公司在中國、美國、新加坡和菲律賓開展業務，由管理團隊領導，該團隊結合了豐富的本地專業知識和生物製藥行業的全球經驗。欲了解更多信息，請訪問investor.ysbiopharma.com。
Investor Relations Contact
投資者關係聯繫人
Alyssa Li
Director of Investor Relations
Email: [email protected]
Alyssa Li
投資者關係董事
電子郵件：[電子郵件保護]
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: [email protected]
楊羅賓
ICR, LLC 合夥人
電話：+1 (212) 537-4035
電子郵件：[電子郵件保護]
SOURCE YS Biopharma Co., Ltd.
來源 YS Biopharma Co., Ltd.